Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

reStoring sIGHt wiTh a neuroprosthEsis for the blinD

Project description

Neural implant restores vision

Vision loss severely limits autonomy and quality of life, particularly for individuals who are completely blind. Existing interventions such as retinal and cortical implants are notably limited in terms of resolution and usability. A more innovative approach focuses on the brain’s visual relay centre, the lateral geniculate nucleus (LGN). By electrically stimulating LGN, the approach aims to deliver more precise visual information. The EIC-funded SIGHTED project aims to validate a next-generation neural implant designed for this purpose. With over 1 000 electrodes, the device is engineered to facilitate high-resolution and wide-field stimulation while minimising surgical risk. The key objective of the project is to advance the implant to clinical readiness and prepare for human testing.

Objective

SIGHTED aims to deliver a breakthrough neural implant to restore functional vision in patients who have lost their sight, enabling them to regain autonomy. Building on the ongoing FET-Open NeuraViPeR project (https://www.neuraviper.eu/(opens in new window)) which concludes in February 2025, SIGHTED will advance our proof-of-concept prototype (TRL 3) to a fully validated implant ready for human testing (TRL 5). Concurrently, we will prepare for commercial adoption by securing regulatory clearance to initiate a First-in-Human study, refining our business model, developing a go-to-market strategy, and preparing for payer coverage and reimbursement.

The neural implant developed in SIGHTED stimulates the lateral geniculate nucleus (LGN), a thalamic nucleus that relays visual information from the retina to the visual cortex. Pioneered by Prof. Dr. Pieter Roelfsema (Institut de la Vision, Sorbonne University, Paris), SIGHTED’s Scientific Coordinator, the implant features a patented ‘Fountain Probe’ capable of distributing electrodes volumetrically within the target structure. With over 1,000 channels—vastly more than the 8-20 channels of existing implants—the Fountain Probe enables precise interventions for conditions like vision and hearing restoration, brain-computer interfacing (BCI), and neuromodulation therapies. Its high resolution, wide field of view, long-term durability, and low surgical risk make it the first solution to meet the critical needs of blind patients.

SIGHTED will help us transition from a prototype to a validated implant for clinical testing. Phosphoenix, a Dutch MedTech SME leading the project, plans to implant the first human patient by early 2027 in a First-in-Human study involving five blind patients. To prepare for a 2032 commercial launch, Phosphoenix will strengthen its IP strategy, secure patents, and explore additional markets beyond blindness, enhancing the Fountain Probe’s commercial potential and positioning it for long-term growth.

Fields of science (EuroSciVoc)

This project has not yet been classified with EuroSciVoc.
Be the first one to suggest relevant scientific fields and help us improve our classification service

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-EIC - HORIZON EIC Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-EIC-2024-TRANSITION-01

See all projects funded under this call

Coordinator

SORBONNE UNIVERSITE
Net EU contribution
€ 776 875,00
Address
21 RUE DE L'ECOLE DE MEDECINE
75006 Paris
France
Region
Ile-de-France Ile-de-France Paris
Activity type
Higher or Secondary Education Establishments
Links
Total cost
No data

Participants (2)